12 results about "3c protease" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to application of anethomycin in preparation of medicine for inhibiting cysteine protease activity. The invention discovers that anethomycin has the function of inhibiting the activity of virus cysteine protease, especially 3C or 3CL protease, for the first time. Molecular docking proves that anethomycin can effectively bind to the catalytic activity center of Senecavirus (SVA) 3C protease. An in-vitro FRET enzyme activity experiment proves that the inhibition rate of 50 [mu] M of anethomycin on SVA 3C protease reaches up to 88.5%. Cellular level experiments show that the anethomycin can significantly inhibit replication of SVA viruses, shows broad-spectrum antiviral activity on various viruses such as encephalomyocarditis viruses (EMCV), porcine reproductive and respiratory syndrome viruses (PRRSV) and porcine deltacoronaviruses (PDCoV), and is low in cytotoxicity and high in selectivity index (SI).

The invention discloses a method for improving the solubility and thermal stability of sweet protein, and belongs to the technical field of biosynthesis, the method comprises the following steps: constructing a gene tandem recombinant plasmid containing a monellin x-3C-sfGFP-3C-monellin y expression cassette, x is greater than or equal to 1, y is greater than or equal to 1, 5 is greater than or equal to x + y is greater than or equal to 3, a 3C protease recognition sequence is also inserted between adjacent copies of monellin, and each monellin is connected with a purification tag; the gene tandem recombinant plasmid is transformed into escherichia coli and inducible expression is carried out, thalli are split and purified to obtain fusion protein, 3C protease is used for enzyme digestion, and the target protein is obtained after re-purification. The total protein yield and the solubility proportion are remarkably improved by adopting a series construction mode of plasmids, meanwhile, the stability of monellin is effectively improved, the purification step is simpler and more convenient, and the method is suitable for industrial production.

The invention relates to the technical field of anti-enterovirus medicines, in particular to application of Enractevir in preparation of an anti-enterovirus medicine. According to the invention, efficient screening of candidate drugs is realized through a multi-channel virus reporting system based on a TAT trans-activation effect, and a small molecule compound drug Enractevir with a specific antiviral effect on enterovirus group A 71 and enterovirus group D 68 is obtained. Enractevir improves the interferon secretion level of host cells by inhibiting the activity of enterovirus 2A / 3C protease, thereby inhibiting virus replication and proliferation. Enractevir plays a role through double-target 2A / 3C protease, and the risk of virus drug resistance can be reduced. According to the technical scheme, the technical problem that in the prior art, specific drugs for the two kinds of enteroviruses are lacked can be solved, a standardized treatment scheme is provided for prevention and control of enterovirus related diseases in the global range, and the medicine has remarkable public health significance and wide application and popularization value.

Vaccine compositions for protecting a subject against diseases caused by viral pathogens of the Picornaviridae family are disclosed. These vaccines comprise nucleic acids encoding the capsid polyprotein (P1 polyprotein) mixed with the viral 3C protease that processes the P1 polyprotein, and encapsulated within nanoparticle carriers. Methods of preventing, reducing, inhibiting, or delaying the symptoms of an infection caused by a viral pathogen, or of inducing an immune response against a viral pathogen in a subject are provided. Methods of making the vaccines are also described.

The application belongs to the field of pharmaceutical chemical industry and relates to a cyclic peptide compound shown as formula M or a stereoisomer, a tautomer or a mixture thereof of the compound, a pharmaceutically acceptable salt, a polymorph, a co-crystal or a solvate of the compound, or a stable isotope derivative, a metabolite or a prodrug of the compound. The application also relates to a method for synthesizing the cyclic peptide compound and an intermediate. The provided cyclic peptide compound has a strong inhibitory effect on a coronavirus 3CL protease and a small RNA virus (for example, an enterovirus EV71 virus) 3C protease. After cell level activity testing, the provided cyclic peptide compound has an obvious inhibitory effect on EV71 virus and coronavirus and the like, indicating that the cyclic peptide compound shown as formula M can produce a viral inhibitory effect at the cell level by inhibiting viral protease activity, and has a good application prospect as an antiviral drug.

A kind of compound containing N-(substituted sulfonyl) acetamide structure as shown in formula I, its pharmaceutically acceptable salt, its isomer, its hydrate or its solvate, and its application as viral protease inhibitor in preparation of antiviral drugs.The provided peptide compound has strong inhibitory effect on coronavirus 3CL protease and small RNA virus (such as enterovirus EV71 virus) 3C protease.Through cell level activity test, the N-(substituted sulfonyl) acetamide structure compound has obvious inhibitory effect on small RNA virus (such as enterovirus EV71 virus) virus and coronavirus, etc., as shown in formula I, the compound containing N-(substituted sulfonyl) acetamide structure can produce viral inhibition effect on cell level by inhibiting viral protease activity, and has good antiviral drug application prospect.

Compounds and treatment methods with dipeptidyl compounds exhibiting antiviral activity and / or inhibition of viral replication against viruses by inhibiting 3CL protease, particularly those belonging to picornavirus, the compounds having a formula:(I) or (I)*.

The invention relates to a recombinant CHO cell strain capable of efficiently inducing and expressing swine foot-and-mouth disease VLP as well as a preparation method and application of the recombinant CHO cell strain. The method comprises the following steps: firstly, screening a monoclonal cell strain capable of stably inducing expression of FMDV 3C protease by taking CHO-B40 (GS defective strain) as a host cell and taking hygromycin and GS as screening markers in a CHO cell strain stable transformation mode, naming the monoclonal cell strain as CHO-FMDV-3C-3D6 cell strain, and then, carrying out recombinant expression of FMDV 3C protease by taking the CHO-FMDV-3C-3D6 cell strain as a host cell. The CHO-FMDV-3C-VLP-4D8 cell strain capable of stably expressing the P12A protein of the foot and mouth disease virus is screened through MSX, the cell strain can only induce expression of 3C protease under the action of an inducer GLP-1 in the culture process, the expressed 3C protease cuts the expressed P12A protein of the FMDV, the cut protein is self-assembled to form FMDV VLP, and the FMDV VLP is separated from the FMDV VLP. The purified VLP and an ISA201 adjuvant are emulsified to prepare an FMDV vaccine, and the FMDV vaccine has good immunogenicity and is beneficial to the development of the swine foot-and-mouth disease virus vaccine industry.

The application discloses a preparation method and application of porcine foot-and-mouth disease O type and A type bivalent virus-like particles, and belongs to the field of biological products. The technical problem to be solved by the application is how to better realize the prevention effect of porcine foot-and-mouth disease. In order to solve the above technical problem, the application provides DNA, wherein the DNA is a gene cluster OVP1-2A-AVP1-3C, and the gene cluster OVP1-2A-AVP1-3C comprises three expression boxes of an expression box of OVP1-2A, an expression box of foot-and-mouth disease virus VP1 of type A and an expression box of 3C protease. The application also provides foot-and-mouth disease bivalent antigens prepared by taking the DNA as a biological material. The foot-and-mouth disease bivalent antigens provided by the application have high immunogenicity in pigs and can induce a strong foot-and-mouth disease antibody response. The research results prove that the immunization antigens provided by the application are effective, and have great industrialization transformation potential and value.

To provide compositions and kits of antiviral agents having different mechanisms of action for treating or preventing viral infections such as COVID-19 (also known as SARS-CoV-2) and for reducing medical complications related to COVID-19 viral disease.SOLUTION: A pharmaceutical composition for treating COVID-19 is provided, comprising: a first antiviral agent consisting of a picornavirus 3C protease inhibitor or a pharmaceutically acceptable salt thereof in a therapeutically effective amount; a second antiviral agent consisting of ritonavir or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and having a different mechanism of action; and a third antiviral agent selected from a group consisting of dexamethasone and remdesivir.SELECTED DRAWING: None

This invention belongs to the field of biomedical technology, specifically relating to lactoferrin peptides and the application of lactoferrin in the preparation of inhibitors of 3C protease. The lactoferrin peptides of this invention contain the amino acid sequence shown in SEQ ID NO.1. The lactoferrin peptides and lactoferrin provided by this invention can specifically bind to and inhibit the activity of 3C protease, directly inhibiting viral replication by blocking its cleavage function of viral polyproteins. The mechanism is clear and has high affinity. Since 3C protease is highly conserved in the Picornaviridae family, it has broad-spectrum inhibitory effects against enteroviruses such as EV-A71 and CV-A9, and has a wide range of applications. Furthermore, it is derived from natural substances, has good biocompatibility and high safety, and can be made into various forms such as pharmaceuticals and antiviral daily necessities, with diverse application scenarios. This invention provides a new approach for developing antiviral drugs targeting 3C protease based on natural proteins, and has significant theoretical and applied value.

The present invention relates to a method of preventing or treating airway inflammation and / or related complications triggered by enterovirus 3C protease activated NLRP1 by using a compound or composition comprising an inhibitor of NLRP1 inflammasome activation. In one embodiment, the enterovirus 3C protease is from a viral species selected from the group consisting of human enterovirus A (HEV-A), human enterovirus B (HEV-B), human enterovirus C (HEV-C), human enterovirus D (HEV-D), human rhinovirus A (HRV-A), human rhinovirus B (HRV-B), and human rhinovirus C (HRV-C). In some embodiments, the compound is selected from the group consisting of MLN 4924, TAS4464, ZM223, MG132, and bortezomib.